Litcius/Paper detail

CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer

Zhiheng Wu, Yu Zheng, Sheng Jin, Yicheng Han, Yanyan Yang, Hongming Pan, Junlin Yao

2022Frontiers in Immunology260 citationsDOIOpen Access PDF

Abstract

The crucial role of CD4 + and CD8 + T cells in shaping and controlling immune responses during immune disease and cancer development has been well established and used to achieve marked clinical benefits. CD3 + CD4 - CD8 - double-negative (DN) T cells, although constituting a rare subset of peripheral T cells, are gaining interest for their roles in inflammation, immune disease and cancer. Herein, we comprehensively review the origin, distribution and functions of this unique T cell subgroup. First, we focused on characterizing multifunctional DN T cells in various immune responses. DN regulatory T cells have the capacity to prevent graft-versus-host disease and have therapeutic value for autoimmune disease. T helper-like DN T cells protect against or promote inflammation and virus infection depending on the specific settings and promote certain autoimmune disease. Notably, we clarified the role of DN tumor-infiltrating lymphocytes and outlined the potential for malignant proliferation of DN T cells. Finally, we reviewed the recent advances in the applications of DN T cell-based therapy for cancer. In conclusion, a better understanding of the heterogeneity and functions of DN T cells may help to develop DN T cells as a potential therapeutic tool for inflammation, immune disorders and cancer.

Topics & Concepts

Immune systemInflammationImmunologyCD8Cytotoxic T cellT cellCancerDiseaseCancer researchBiologyMedicinePathologyBiochemistryGeneticsIn vitroCAR-T cell therapy researchImmune Cell Function and InteractionT-cell and B-cell Immunology
CD3+CD4-CD8- (Double-Negative) T Cells in Inflammation, Immune Disorders and Cancer | Litcius